On March 7, 2025, Vaccinex, Inc. (OTC: VCNX) revealed its intention to delist its common stock from the Nasdaq Stock Market. The clinical-stage biotech company halted trading of its stock on Nasdaq since December 18, 2024, due to its innovative approach in treating neurodegenerative diseases. By inhibiting SEMA4D, Vaccinex aims to combat astrogliosis and neuroinflammation. The company's decision to delist follows the notification provided to Nasdaq.
